Divalproex sodium is a stable coordination compound comprised of sodium valproate and valproic acid in a 1:1 molar ratio. It is a broad-spectrum antiepileptic drug (AED) and a first-line mood stabilizer. In the Indian context, it is a critical agent for managing epilepsy, bipolar disorder, and migraine prophylaxis. It functions primarily by increasing brain levels of the inhibitory neurotransmitter GABA and modulating voltage-gated sodium channels.
Adult: Epilepsy: Initial dose 10-15 mg/kg/day in 1-2 divided doses, increase by 5-10 mg/kg/week. Usual maintenance: 1000-2000 mg/day (20-30 mg/kg/day). Bipolar Mania: Start at 750 mg/day in divided doses, titrate rapidly to achieve clinical response. Max recommended: 60 mg/kg/day. Migraine: Start at 500 mg/day, may increase to 1000 mg/day. Doses > 1000 mg/day show no increased benefit.
Note: Delayed-release (enteric-coated) tablets must be swallowed whole, not crushed or chewed. Can be taken with or without food to improve GI tolerance. If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double the dose.
The exact mechanism is multifactorial and not fully elucidated. Primary actions include: 1) Increasing availability of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase, and possibly enhancing GABA synthesis. 2) Modulating voltage-gated sodium channels, reducing sustained, high-frequency neuronal firing. 3) Attenuating N-methyl-D-aspartate (NMDA) receptor-mediated excitatory neurotransmission. 4) Inhibition of histone deacetylases (HDACs), which may contribute to its neuroprotective and mood-stabilizing effects.
Pregnancy: Pregnancy Category D (for epilepsy/bipolar) and X (for migraine). Major teratogen. Risk of neural tube defects (spina bifida) ~1-2%. Other risks: craniofacial defects, cardiovascular malformations, cognitive impairment, and autism spectrum disorder. Folic acid supplementation (5 mg/day) must be started pre-conception. Use only if benefits outweigh significant risks. TDM essential as clearance increases during pregnancy.
Driving: May cause dizziness, drowsiness, and blurred vision. Patients should be cautioned not to drive or operate heavy machinery until they know how the drug affects them, especially during dose titration.
| Carbamazepine, Phenytoin, Phenobarbital | Decreases valproate levels by inducing metabolism | Major |
| Lamotrigine | Valproate inhibits lamotrigine metabolism, doubling its half-life; increases risk of serious rash (SJS/TEN) | Major |
| Clonazepam | May induce absence status epilepticus | Moderate |
| Warfarin, Aspirin | Displaces valproate from protein binding sites, increasing free fraction; Aspirin also inhibits metabolism, increasing toxicity risk | Major |
| Topiramate | Increased risk of hyperammonemia and encephalopathy | Moderate |
| Meropenem, Panipenem (Carbapenem antibiotics) | Dramatically reduce valproate levels by ~60-90%, potentially causing seizure breakthrough | Major |
| Clozapine | Increased risk of neutropenia and sedation | Moderate |
| Oral Contraceptives (Ethinyl Estradiol) | Valproate may decrease estrogen levels, potentially reducing contraceptive efficacy (data conflicting) | Moderate |
Same composition (Divalproex (500mg)), different brands: